Lilly's Omvoh met its Phase III primary endpoint in pediatric ulcerative colitis, with 50% of responders in remission at Week ...
Gilead's oral α4β7 integrin inhibitor emvistegrast met the primary endpoint in Phase II SWIFT study for ulcerative colitis.
Evaxion's personalized cancer vaccine EVX-01 kept all Phase II melanoma patients in response at three years, with no tumor ...
AbbVie (NYSE: ABBV) reported that its investigational dual-targeting combination ABBV-466 achieved primary endpoints in ...
FDA grants accelerated approval to GSK's Jemperli for stage II/III MSI-H or dMMR locally advanced rectal cancer. Read what this means for patients today.
FDA grants orphan drug designation to GT801, an in vivo CAR-T for AIHA. Read how this Vivacta and Grit Bio therapy could ...
FDA unveils Rare Disease Framework Initiative to overhaul how rare-condition drugs are developed and reviewed. See how it ...
FDA approves Ryzumvi label expansion for presbyopia, giving Viatris' phentolamine eye drop a second indication. Read the full details and clinical impact.
Nouscom closes oversubscribed EUR 120M Series D to advance NOUS-209 toward a Lynch syndrome registration trial. Learn what this means for patients.
Microbiotica raised USD 48m in its Series C to advance MB310 into a Phase II ulcerative colitis study. Read the complete ...
Betta pan-RAS inhibitor BPI-572270 wins NMPA combination trial acceptance in China, plus Australian and US FDA trial ...
OrbiMed raises USD 3 billion across two private equity funds targeting life sciences and healthcare in the US, Europe, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results